{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:26:39Z","timestamp":1782858399728,"version":"3.54.5"},"reference-count":32,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The prevalence of carbapenem-resistant <jats:italic>Enterobacteriaceae<\/jats:italic> (CRE) infections is increasing worldwide. However, the evidence regarding the treatment of infections caused by CRE is either low or conditional.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This multicentre, investigator-initiated, open-label, randomised controlled, non-inferiority trial compares colistin-based combination therapy with the best available therapy for treating CRE infections. This study is being conducted at 15 centres in China. We include participants with hospital-acquired pneumonia (HAP) or bloodstream infections (BSI) caused by CRE. Participants will be randomly assigned to a colistin-based combination therapy group or the best available therapy group. The primary outcome is the 14-day all-cause mortality. Secondary outcomes include 14-day clinical cure rate, 14-day efficacy rate, intensive care unit (ICU)-free days within 28 days after randomisation, 14-day microbiological cure rate, incidence of adverse events (AEs) and serious AEs within the first 28 days, hospital mortality, 28-day all-cause mortality and ICU mortality. A target sample size of 404, with 322 evaluable patients (161 in each group) allowed for at least 80% power (one-sided significance level of 0.025), assuming a 15% non-inferiority margin and a 14-day all-cause mortality rate of 35% in both groups. Primary outcome will be assessed based on the microbiologically modified intent-to-treat, and one interim analysis is planned when 50% of the participants have been enrolled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The study was approved by the Research Ethics Boards at Zhongda Hospital (file number: 2023ZDSYLL295-P03) and all participating centres. Informed consent will be obtained from all participants. The trial will be conducted under the oversight of an independent data and safety monitoring committee. Results will be disseminated in peer-reviewed journals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06051513\">NCT06051513<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092157","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:10:48Z","timestamp":1752657048000},"page":"e092157","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Multicentre open-label randomised controlled trial comparing the efficacy and safety of colistin-based combination therapy with the best available therapy for treating hospital-acquired pneumonia or bloodstream infections caused by carbapenem-resistant <i>Enterobacteriaceae<\/i> (COUNT-CRE): a study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06051513","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-7949","authenticated-orcid":false,"given":"Xiangquan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, The Xuzhou School of Clinical Medicine of Nanjing Medical University, Xuzhou, Jiangsu, People's Republic of China"},{"name":"Department of Intensive Care Unit, Xuzhou Central Hospital, Xuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7183-6233","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-1600","authenticated-orcid":false,"given":"Jiaqiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Xuzhou School of Clinical Medicine of Nanjing Medical University, Xuzhou, Jiangsu, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-6450","authenticated-orcid":false,"given":"Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, School of Public Health, Xi\u2019an Jiaotong University Health Science Center, Xi\u2019an, Shanxi, People's Republic of China"},{"name":"Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, XI\u2019an, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-9172","authenticated-orcid":false,"given":"Jianfeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-3580","authenticated-orcid":false,"given":"Yingzi","family":"Huang","sequence":"additional","affiliation":[{"name":"Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China"},{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025071602102725000_15.7.e092157.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02724-0"},{"key":"2025071602102725000_15.7.e092157.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106103"},{"key":"2025071602102725000_15.7.e092157.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201102-0349OC"},{"key":"2025071602102725000_15.7.e092157.4","doi-asserted-by":"publisher","DOI":"10.1016\/J.CMI.2019.10.031"},{"key":"2025071602102725000_15.7.e092157.5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"key":"2025071602102725000_15.7.e092157.6","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.2147\/IDR.S395920","article-title":"Genetic and Phenotypic Characteristics of Carbapenem-Resistant Klebsiella pneumoniae Isolates from a Tertiary Hospital in Beijing","volume":"15","author":"Ni","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025071602102725000_15.7.e092157.7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40121-022-00732-7","article-title":"Retrospective Analysis of Epidemiology, Risk Factors, and Outcomes of Health Care-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in a Chinese Tertiary Hospital, 2010-2019","volume":"12","author":"Li","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025071602102725000_15.7.e092157.8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025071602102725000_15.7.e092157.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"2025071602102725000_15.7.e092157.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025071602102725000_15.7.e092157.11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajt.2023.03.011","article-title":"Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae","volume":"23","author":"P\u00e9rez-Nadales","year":"2023","journal-title":"Am J Transplant"},{"key":"2025071602102725000_15.7.e092157.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.016"},{"key":"2025071602102725000_15.7.e092157.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"2025071602102725000_15.7.e092157.14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025071602102725000_15.7.e092157.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"2025071602102725000_15.7.e092157.16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s15010-023-02108-6","article-title":"Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"52","author":"Chen","year":"2024","journal-title":"Infection"},{"key":"2025071602102725000_15.7.e092157.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.07.004"},{"key":"2025071602102725000_15.7.e092157.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"key":"2025071602102725000_15.7.e092157.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-04116-8","article-title":"Clinical validation of a multiplex droplet digital PCR for diagnosing suspected bloodstream infections in ICU practice: a promising diagnostic tool","volume":"26","author":"Wu","year":"2022","journal-title":"Crit Care"},{"key":"2025071602102725000_15.7.e092157.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy988"},{"key":"2025071602102725000_15.7.e092157.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"2025071602102725000_15.7.e092157.22","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"2025071602102725000_15.7.e092157.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"2025071602102725000_15.7.e092157.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070491","article-title":"Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis","volume":"13","author":"Yang","year":"2023","journal-title":"BMJ Open"},{"key":"2025071602102725000_15.7.e092157.25","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02218-22","article-title":"Multicenter Study of Colistin Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae Strains in China","volume":"11","author":"Weng","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025071602102725000_15.7.e092157.26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/QCO.0000000000000495","article-title":"Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"31","author":"Carrara","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2025071602102725000_15.7.e092157.27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","article-title":"Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes","volume":"26","author":"Nutman","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2025071602102725000_15.7.e092157.28","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.2147\/IDR.S409964","article-title":"Comprehensive Assessment of Colistin Induced Nephrotoxicity: Incidence, Risk Factors and Time Course","volume":"16","author":"Rabi","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025071602102725000_15.7.e092157.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"2025071602102725000_15.7.e092157.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"2025071602102725000_15.7.e092157.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.014"},{"key":"2025071602102725000_15.7.e092157.32","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/cid\/ciz1146","article-title":"Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms","volume":"71","author":"Dickstein","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:10:51Z","timestamp":1752657051000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-092157"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092157","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}